os after progression on first novel hormonal therapy in mcspc vs mcrpc
Published 2 years ago • 88 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
5:10
mcspc: treatment after progression on ar-targeted therapy
-
2:24
survival outcomes and characterization of mcspc
-
1:06
dr. hamid on the progression of therapy for metastatic prostate cancer
-
7:52
case 3: treatment after progression to mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
5:23
stories of advanced prostate cancer remissions | ask a prostate cancer expert, mark scholz, md
-
20:40
advanced prostate cancer story: jan manarite advocated for her husband for 13 years
-
22:01
chemotherapy in #prostatecancer | the psa response & side effects | #markscholzmd #alexscholz
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
23:36
novel hormonal therapies for prostate cancer
-
1:26
current standards and future prospects for the treatment of hormone refractory prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
6:12
peace-1 trial
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:36
genomic characterization of patients with de-novo high-volume mcspc compared to those without
-
25:01
case study 1: hormone-sensitive, metastatic crpc
-
39:02
systemic therapies for the treatment of advanced prostate cancer
-
5:20
nicholas vogelzang, md, on card study impressions comparing novel hormonal therapy to cabazitaxel
-
2:30
parp inhibitors plus novel endocrine agents for patients with metastatic prostate cancer